37 results
8-K
EX-99.1
BACK
IMAC Holdings Inc
24 May 24
IMAC Holdings Announces Leadership Succession
9:00am
phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. Its LDTs
S-4/A
BACK
IMAC Holdings Inc
9 Nov 23
Registration of securities issued in business combination transactions (amended)
5:31pm
,” “anticipates,” “indicates,” “remains,” “believes,” “estimates,” “forecast,” “guidance,” “outlook,” “goals,” “targets” and other similar expressions … of either predictive, prognostic, or diagnostic. Biomarkers serve as the drug targets for most FDA-approved and investigational therapies for cancer
S-4
vgt0 a8vkeevkso8q4xg
29 Sep 23
Registration of securities issued in business combination transactions
5:13pm
8-K
EX-99.1
vzkn2dfq
28 Jul 23
IMAC Holdings Announces $4.3 Million Private Placement of Convertible Preferred Stock and Warrants Priced at the Market
5:00pm
425
EX-99.1
z2viuvbv7kj0b1eyopa
26 May 23
Business combination disclosure
5:05pm
8-K
EX-99.1
87dtssoi 3r
26 May 23
Theralink® Signs Definitive Merger Agreement to be Acquired by IMAC Holdings, a Nasdaq Listed Company
5:01pm
424B5
cdh2k5ienzpy3y8k6j
15 Aug 22
Prospectus supplement for primary offering
4:51pm
424B4
kkiuv63mfjz6mkd6cl
24 Mar 21
Prospectus supplement with pricing info
3:38pm
424B5
9hybb47kx
5 Oct 20
Prospectus supplement for primary offering
5:04pm
424B5
kjth02 nv1
19 Jun 20
Prospectus supplement for primary offering
12:00am
424B3
ueeiik31nvajvxzs
22 Aug 19
Prospectus supplement
4:06pm